• English
    • español
    • português (Brasil)
  • English 
    • English
    • español
    • português (Brasil)
  • Login
View Item 
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Atypical antibiotics alone seem no better for mortality and clinical efficacy than typical antibiotics alone in patients with community acquired pneumonia

 
Thumbnail
Date
2020-03-19
Author
Allen, Claire
Metadata
Show full item record
Abstract
What is this? Some patients with COVID-19 will develop pneumonia and evidence from studies of the treatment of community acquired pneumonia (CAP) may be of help in treating such patients. CAP is a serious lung infection, usually treated with antibiotics. Two types of bacteria cause CAP: ‘typical’ and ‘atypical’, each requiring a different type of antibiotic, but initial treatment of CAP is usually empirical, using a drug that covers both typical and atypical bacteria. In this Cochrane systematic review, the authors searched for randomized or quasi-randomized trials comparing antibiotic regimens containing atypical antibiotics versus those that had typical coverage only. They did not restrict by language of publication and did their searches in April 2012. They included 28 studies (5939 patients).
URI
https://www.evidenceaid.org/atypical-antibiotics-alone-seem-no-better-for-mortality-and-clinical-efficacy-than-typical-antibiotics-alone-in-patients-with-community-acquired-pneumonia
Collections
  • Technical documents and research evidence on COVID-19

Browse

AllCommunities & CollectionsBy Issue DateAuthorsTitlesCategorySubjectsThis CollectionBy Issue DateAuthorsTitlesCategorySubjects

My Account

LoginRegister

Pan American Health Organization
World Health Organization. Regional Office for the Americas
525 Twenty-third Street, N.W., Washington, D.C. 20037, United States of America

Content Disclaimer (Important notes about the material)

Links

  • WHO International Clinical Trial Registry Platform (ICTRP)
  • WHO Coronavirus disease R&D Blueprint
  • WHO Database of Publications on Coronavirus Disease
  • PAHO Coronavirus Disease
  • PAHO/BIREME Windows of Knowledge COVID-19
  • Evidence aid Coronavirus (COVID-19) resources

  • PAHO Digital Library (IRIS PAHO)
  • Virtual Health Library (VHL)
  • Global Index Medicus (GIM)